Sanofi said on Wednesday it will buy U.S. biotech Dynavax Technologies for around $2.2 billion (1.9 billion euros) in an agreed deal that will add an adult hepatitis B vaccine and a promising experimental shingles shot to its portfolio.

The cash deal seeks to strengthen the French drugmaker’s immunization portfolio after it suffered setbacks in clinical trials.

Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday

Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction valued at approximately $2.2 billion, marking another strategic move to expand its vaccines